Page 383 - Bloedstollig en bloedingsneiging

Noten 371
blood coagulation (Rochester, Minn.: Mayo Foundation for Medical Education and Research, 2001), p. 149. x–25: J. Koutts, ‘A short history of diagnostic tests for von Willebrand Disease: In Memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988)’, Seminars in thrombosis and hemostasis 32 (2006), 445-55.
x–26: B.N. Bouma, Y. Wiegerinck, J.J. Sixma, J.A. van Mourik en I.A. Mochtar, ‘lmmunological characterization of purified anti-haemophilic factor A (Factor VIII) which corrects abnormal platelet retention in von Willebrand’s Disease’, Nature new biology 236 (1972), 104-6.
x–27: H.J. Weiss en I.W. Hoyer, ‘Von Willebrand factor: Dissociation from antihemophilic factor procoagulant activity’, Science 182 (1973), 1149-51.
x–28: H. Stormorken, Paul A. Owren & The golden era of haemostasis (Oslo: Gazettebok, 2005), p. 140 resp. p. 155.
x–29: B.N. Bouma, J.A. van Mourik, J.J. Sixma, I.A. Mochtar, Y. Wiegerinck en S. de Graaf, ‘Von Willebrand factor and antihaemophilic factor A (factor VIII)’, Thrombosis et diathesis haemorrhagica, Suppl. 54 (1973), 191-6; B.N. Bouma, J.J. Sixma, S. de Graaf, J.A. van Mourik en I.A. Mochtar, ‘Factor VIII antigen and platelet retention in a glass bead column’, British journal of haematology 25 (1973), 645-56; B.N. Bouma, J.A. van Mourik, Y. Wiegerinck, J.J. Sixma en I.A. Mochtar, ‘Immunological characterization of antihemophilic factor A (factor VIII) related antigen in haemophilia A’, Scandinavian journal of haematology 11 (1973), 184-7; B.N. Bouma, J.J. Sixma, J.A. van Mourik en I.A. Mochtar, ‘Antigen / biological activity ratio for factor VIII - Letter to the editor’, The Lancet (1001) (May 5, 1973).
x–30: H.R. Roberts, et al., ‘In memoriam: Kenneth M. Brinkhous (1908-2000)’, Thrombosis research 102 (2001), 385-6.
x–31: S. Aldridge, ‘Dogs’ priceless contribution to hemophilia research: Hemophilia treatment in humans developed in parallel with dogs’, Hemaware / The bleeding disorders magazine (2010).
x–32: Zie ook: B.N. Bouma, S. de Graaf, J.M. Hordijk-Hos, J.A. van Mourik en J.J. Sixma, ‘Investigations on the relationship of factor VIII related antigen, factor VIII procoagulant activity and von Willebrand factor activity using insolubilized rabbit antiserum’, Thrombosis research 7 (1975), 695-707.
x–33: B.N. Bouma, Von Willebrand factor and factor VIII (Utrecht: Universiteit Utrecht, 1974); J.A. van Mourik, Investigations on the purification and characterization of human anti-hemophilic factor A (factor VIII) - dissertatie (Amsterdam: J. Kaal, 1975).
x–34: J. Meijers, K. van ‘t Veer en T. Hackeng, ‘Bonno Bouma’, in: T. Hackeng, et al., NVTH - 25 jaar - 25 years (Utrecht: NVTH, 2013), pp. 71-8.
x–35: Interview met Bonno Bouma (december 2013).
x–36: B.N. Bouma en J.H. Griffin, ‘Human blood coagulation factor XI: Purification, properties, and mechanism of activation by activated factor XII’, Journal of biological chemistry 252 (1977), 6432-7.
x–37: J. Meijers, K. van ‘t Veer en T. Hackeng, ‘Bonno Bouma’, in: T. Hackeng, et al., NVTH - 25 jaar - 25 years (Utrecht: NVTH, 2013), pp. 71-8.
x–38: J.A. van Mourik, B.N. Bouma, W.T. LaBruyère, S. de Graaf en I.A. Mochtar, ‘Factor VIII, a series of homologous oligomers and a complex of two proteins’, Thrombosis research 4 (1974), 155-64.
x–39: H. Stormorken, Paul A. Owren & The golden era of haemostasis (Oslo: Gazettebok, 2005), p. 155.
x–40: Email van J.J. Sixma aan de auteur (2 januari 2015).
x–41: J. Over, Functional heterogeneity of human factor VIII (Utrecht: Universiteit Utrecht, 1978).
x–42: Zie ook: J.B. Graham, W.B. McLester, K. Pons, H.R. Roberts and E.M. Barrow, ‘Genetics of vascular hemophilia and biosynthesis of the plasma antihemophilic factor’, in: The Hemophilias, International Symposium (Washington, 1964), pp. 263-75.
x–43: J.J. Sixma, J. Over, B.N. Bouma, A.L. Bloom en I.R. Peake, ‘Predominance of normal low molecular weight forms of factor VIII in ‘variant’ von Willebrand’s disease’, Thrombosis research 12 (1978), 929-35.
x–44: B.N. Bouma, S. de Graaf, J.W. Slot en T.S. Zimmerman, ‘Human blood platelet factor VIII-related antigen: Demonstration of release by alpha-chymotrypsin’, Thrombosis research 14 (1979), 687-96.
x–45: R.J. Hamer, FVIII isolation, characterization and interaction with von Willebrand factor (Utrecht: UU, 1986); J.A. Koedam, Interaction between factor VIII and von Willebrand factor (Utrecht: Universiteit Utrecht, 1989).
x–46: Maar zie: J.J. Sixma, R.J. Hamer en J. Koedam, ‘Nieuwe inzichten in de biologie van factor VIII’, Nederlands tijdschrift voor geneeskunde 130 (1986), 2026-30.
Hoofdstuk XI
xi–1: R.E. Kohler, From medical chemistry to biochemistry: The making of a biomedical discipline (Cambridge: Cambridge University Press, 1982), p. 92; nadruk toegevoegd.
xi–2: Voor Kohlers uitgebreide werk aan de geschiedenis van de biochemie, zie bijvoorbeeld: R.E. Kohler, ‘The enzyme theory and the origin of biochemistry’, Isis 64 (1973), 181-96; idem, ‘The history of biochemistry: A survey’, Journal of the history of biology 8 (1975), 275-318; idem, ‘Walter Fletcher, F. G. Hopkins and the Dunn